Blocking cGAS Slows ALS Progression Driven by TDP-43 Pathology
A new cGAS inhibitor reduces toxic TDP-43 buildup, preserves motor neurons, and reverses RNA splicing defects in ALS models.
Summary
Researchers identified cGAS, an innate immune enzyme, as a key driver of TDP-43 pathology in ALS. Using human iPSC-derived microglia and motor neuron co-cultures plus TDP-43 Q331K transgenic mice, they showed that cGAS is elevated in ALS patient microglia and that its inhibition reduces phosphorylated TDP-43, restores lysosomal and phagocytic function, preserves motor neurons, and reverses widespread RNA splicing defects. A potent human-selective cGAS inhibitor (SS-1386) and a mouse-selective compound (TDI-6570) both demonstrated therapeutic effects, selectively benefiting TDP-43-driven models but not SOD1-G93A mice, suggesting cGAS is specifically relevant to TDP-43 proteinopathy rather than all forms of ALS.
Detailed Summary
ALS kills motor neurons progressively and currently has no cure, with most cases featuring toxic cytoplasmic clumps of the RNA-binding protein TDP-43. Understanding what triggers and amplifies TDP-43 pathology is critical for developing better therapies. This study positions cGAS — best known as a cytosolic DNA sensor that launches innate immune responses — as an upstream instigator of TDP-43-driven neurodegeneration.
The researchers first mined single-cell RNA sequencing data from postmortem human ALS brains, finding that microglia shift from homeostatic to activated states in ALS, with cGAS expression and interferon-stimulated gene signatures markedly elevated in disease-associated microglial clusters. Human iPSC-derived microglia carrying ALS-linked TARDBP-Q331K or C9orf72 expansions also showed elevated cGAS mRNA autonomously, validating the human tissue observations in a tractable model.
To test whether cGAS inhibition could reverse this dysfunction, the team developed SS-1386, a brain-permeable human-selective cGAS inhibitor with an IC50 of 71 nM. In iPSC-derived microglia–motor neuron co-cultures, cGAS inhibition reduced phosphorylated TDP-43, restored lysosomal acidification and phagocytic clearance of myelin debris, normalized microglial reactivity, and partially reversed TDP-43-associated RNA splicing defects in motor neurons. These effects were recapitulated with CGAS knockout, confirming on-target activity.
In vivo, TDP-43 Q331K transgenic mice treated with the mouse-selective cGAS inhibitor TDI-6570 from 6 weeks of age showed significantly improved motor coordination on rotarod testing, reduced serum neurofilament light chain (a biomarker of axonal damage), lower spinal cord phospho-TDP-43 levels, and better preservation of choline acetyltransferase-positive motor neurons compared to untreated Q331K mice. Metabolic profiling also revealed that cGAS inhibition normalized the elevated energy expenditure and excessive weight gain characteristic of Q331K mice. Importantly, cGAS inhibition also benefited a second TDP-43 model (TARDBP-A315T) but showed no protective effect in SOD1-G93A mice, indicating specificity for TDP-43-driven pathology. Transcriptomic analysis revealed that cGAS inhibition reversed widespread RNA splicing abnormalities across neurons and oligodendrocyte lineage cells.
These findings establish cGAS as a druggable upstream node linking microglial innate immune activation to TDP-43 pathology and RNA dysregulation, and identify cGAS inhibition as a mechanistically coherent therapeutic strategy. The study is a preprint and will need peer-reviewed validation, and long-term safety and CNS exposure data for the human inhibitor remain to be fully characterized.
Key Findings
- cGAS expression is markedly elevated in ALS patient microglia and correlates with interferon signaling activation.
- Human cGAS inhibitor SS-1386 (IC50 71 nM) reduces phospho-TDP-43 and restores microglial lysosomal/phagocytic function in iPSC co-cultures.
- cGAS inhibition preserved motor neurons and improved rotarod performance in TDP-43 Q331K mice from 6–28 weeks.
- Treatment reversed widespread RNA splicing defects in neurons and oligodendrocyte lineage cells in vivo.
- Protective effects were TDP-43 specific — no benefit observed in SOD1-G93A mice.
Methodology
The study combined single-cell RNA sequencing of postmortem human ALS brains, human iPSC-derived microglia–motor neuron co-cultures (with pharmacological and genetic cGAS perturbation), and in vivo treatment of TDP-43 Q331K and A315T transgenic mice with a mouse-selective cGAS inhibitor delivered dietarily from 6 to 32 weeks of age. Outcomes included behavioral (rotarod), metabolic (indirect calorimetry), proteomic (pTDP-43, NFL ELISA), histological (ChAT immunofluorescence), and transcriptomic (bulk RNA-seq, splicing analysis) endpoints.
Study Limitations
This is a preprint and has not yet undergone peer review. The human-selective inhibitor SS-1386 lacks published long-term CNS pharmacokinetic and safety data. The in vivo work used only mouse-selective inhibitors, so direct translation of human cGAS inhibitor efficacy in a living organism remains to be demonstrated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: